Menopause Emerges as a Key Factor in Shaping Multiple Sclerosis Presentation and Comorbidity Profiles
A groundbreaking study unveiled at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) in Barcelona sheds new light on how menopause distinctly influences the clinical manifestation and associated health complications in women diagnosed with multiple sclerosis (MS). This seminal research, conducted by Yasemin Şimşek and her team, offers compelling evidence that hormonal changes inherent to menopause modulate not only the initial symptomatic landscape of MS but also the burden and nature of comorbidities encountered, signaling a paradigm shift towards more nuanced, life-stage-tailored therapeutic approaches.
Multiple sclerosis, a chronic autoimmune disorder characterized by demyelination and neurodegeneration within the central nervous system, disproportionately affects women, with disease progression known to intersect significantly with sex-specific biological variables. Yet, despite established differences in disease trajectory between sexes, the role of menopause—a critical hormonal milestone—in dictating the onset and evolution of MS symptoms had remained underexplored until this pivotal investigation.
The study meticulously analyzed a robust dataset comprising 864 patients from a larger cohort of 4,191 individuals. Within this subset, 298 were premenopausal women, 300 postmenopausal women, and 265 age-matched men, providing a comprehensive lens through which to compare initial disease presentation across gender and menopausal status. Advanced statistical methods were employed to parse out subtle divergences in symptom topography and comorbid condition patterns, with a specific focus on neuroinflammatory versus neurodegenerative mechanisms underpinning MS symptomatology.
Intriguingly, the analysis delineated a pronounced predilection for the optic nerve as the inaugural site of clinical symptoms in premenopausal women, with a striking 21.8% presenting with optic neuritis. This was contrasted with a notably lower incidence in postmenopausal women (15%) and men (11.7%). Conversely, spinal cord involvement as the initial manifestation was predominant in postmenopausal women (44%) and men (48.3%), surpassing the 27.5% observed in their premenopausal counterparts. These findings implicate the modulatory influence of oestrogen and other sex hormones on regional vulnerability within the central nervous system, potentially through neuroprotective pathways and immune response calibration.
Şimşek elucidated that these divergent patterns likely reflect the complex interplay between hormonal status, immune system dynamics, and intrinsic neuroprotective mechanisms. Premenopausal women, bolstered by higher circulating oestrogen levels, may mount more vigorous inflammatory responses resulting in acute optic nerve involvement. Meanwhile, postmenopausal women and men might experience a more insidious onset attributable to progressive neurodegeneration and attenuated immune modulation, predominantly impacting the spinal cord.
A further layer of differentiation was observed in comorbidity profiles. Premenopausal women exhibited a relatively low prevalence (15.1%) of concomitant disorders, whereas this figure escalated sharply to 41% among postmenopausal women and 36.6% in men. Cardiovascular pathologies, including hypertension, arrhythmias, and coronary artery disease, emerged as the foremost comorbid conditions in the postmenopausal cohort, afflicting nearly a quarter (24.7%). Additionally, endocrine and metabolic disturbances such as type 2 diabetes mellitus, hypothyroidism, and dyslipidaemia were prominent in 10.3% of postmenopausal women, highlighting the metabolic shifts associated with endocrine senescence.
In stark contrast, the psychiatric domain revealed an inverse pattern; depression and anxiety disorders were more prevalent in premenopausal women, suggesting differential psychosocial stressors and neurochemical milieu influenced by reproductive hormones. These psychiatric comorbidities may correlate with earlier disease onset and heightened disease activity, warranting comprehensive psychological assessment and intervention in this demographic.
Men’s comorbidity spectrum bore closer resemblance to postmenopausal women, underscoring the role of diminished sex hormone levels and aging-related cardiovascular risk in shaping MS complications. The convergence of these patterns underscores the necessity of integrating sex, age, and hormonal status in the clinical management of MS.
Mortality data from the study period further reinforced these distinctions: no deaths were recorded among premenopausal women, whereas 15 men and 9 postmenopausal women succumbed, reflecting the compounded vulnerability linked to advancing age and comorbidity accumulation. Such findings emphasize the imperative for stratified risk assessment and targeted prevention strategies.
In practical terms, Şimşek advocates for differentiated clinical pathways: men and postmenopausal women should be prioritized for interventions aimed at curbing neurodegeneration and mitigating disability progression. Conversely, premenopausal women require vigilant surveillance of relapse activity alongside optimization of disease-modifying therapies to control inflammation and preserve neurological function.
The translational implications of this research are profound, advocating for a shift from a one-size-fits-all framework toward precision medicine in MS care. By acknowledging and harnessing the biological nuances imparted by menopause, clinicians can refine therapeutic regimens, enhance quality of life, and potentially alter disease trajectories in affected women.
This landmark study not only enriches our understanding of hormonal influences on autoimmune neuroinflammation but also paves the way for multidisciplinary collaborations integrating neurology, endocrinology, psychiatry, and cardiovascular medicine to holistically address the complex needs of MS patients across the lifespan.
Yasemin Şimşek’s work embodies a significant stride forward in neuroimmunology research, melding clinical insight with rigorous data analysis to illuminate the intersection of gender, aging, and disease dynamics. As the global MS community converges in forums such as ECTRIMS, this research will undoubtedly catalyze further investigations and inspire innovative, patient-centered care models attuned to life-stage transitions.
Subject of Research: The impact of menopause on initial clinical presentation and comorbidities in women with multiple sclerosis, compared with age-matched men.
Article Title: Impact of Menopause on Initial Clinical Presentation and Comorbidities in Women with Multiple Sclerosis: A Comparative Study with Age-Matched Men.
News Publication Date: 25 September 2025
References:
Şimşek SY. Impact of Menopause on Initial Clinical Presentation and Comorbidities in Women with Multiple Sclerosis: A Comparative Study with Age-Matched Men. Presented at ECTRIMS 2025, Barcelona, Spain.
Keywords:
Multiple sclerosis, autoimmune disorders, neuroimmunology, menopause, hormonal influence, disease-modifying therapy, optic neuritis, spinal cord, comorbidities, cardiovascular disease, psychiatric disorders, neurodegeneration, sex differences
Tags: chronic autoimmune disorder researchclinical manifestation of MScomorbidities in multiple sclerosisECTRIMS 2025 findingshormonal changes and MS symptomshormonal milestones in women’s healthimpact of menopause on health conditionslife-stage-tailored treatment for MSmenopause and multiple sclerosisneurodegeneration and menopausesex differences in autoimmune disorderswomen’s health and MS
